Literature DB >> 24873924

A clinical overview of non-motor symptoms in Parkinson's Disease.

Nicola Modugno1, Francesco Lena, Francesca Di Biasio, Gloria Cerrone, Stefano Ruggieri, Francesco Fornai.   

Abstract

Although Parkinson's disease (PD) is diagnosed on the basis of motor symptoms, including slowness of movement, tremor, rigidity and difficulties with balance and walking, now we are aware that non-motor symptoms are highly prevalent, since they can anticipate motor symptoms and can cause severe consequences. Several studies have shown that non-motor symptoms, such as depression, anxiety and apathy, psychosis (e.g., hallucinations, delusions), sleep disturbance, and pain may have a greater adverse impact on quality of life and health economics compared with motor symptoms. Non-motor symptoms can be divided into four domains: neuropsychiatric (e.g., depression, anxiety, apathy, hallucinations, dementia), autonomic (e.g., constipation, orthostatic hypotension, urinary changes, sweating abnormalities), sleep (e.g., insomnia, sleep fragmentation, excessive daytime sleepiness, rapid eye movement, sleep behavioural disorder, restless leg syndrome), and sensory dysfunction (e.g., pain, olfactory dysfunction). This review addresses diagnosis and treatment of these disorders. The causative mechanisms remain complex, since they reflect the widespread brainstem and cortical pathology of PD, with involvement of several neurotransmitters, including dopamine (DA), serotonin, norepinephrine, and acetylcholine. The diagnosis is often challenging, especially for psychiatric disorders, and in particular affective disorders, because somatic features of psychopathology may overlap with the movement disorder itself. Treatments used are limited and psychiatric drugs may not be as effective as in general population. Evidence based medicine is quite poor and it still requires well-designed clinical studies.

Entities:  

Year:  2013        PMID: 24873924

Source DB:  PubMed          Journal:  Arch Ital Biol        ISSN: 0003-9829            Impact factor:   1.000


  8 in total

1.  Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson's disease.

Authors:  Fardin Nabizadeh; Fatemeh Sodeifian; Kasra Pirahesh
Journal:  Neurol Sci       Date:  2022-05-04       Impact factor: 3.830

2.  Downregulation of CDK5 signaling in the dorsal striatum alters striatal microcircuits implicating the association of pathologies with circadian behavior in mice.

Authors:  Hu Zhou; Jingxin Zhang; Huaxiang Shi; Pengfei Li; Xin Sui; Yongan Wang; Liyun Wang
Journal:  Mol Brain       Date:  2022-06-14       Impact factor: 4.399

Review 3.  Psychiatric aspects of Parkinson's disease.

Authors:  Sandeep Grover; Mansi Somaiya; Santhosh Kumar; Ajit Avasthi
Journal:  J Neurosci Rural Pract       Date:  2015-01

4.  Use of Fall-Risk Inducing Drugs in Patients Using Anti-Parkinson Drugs (APD): A Swedish Register-Based Study.

Authors:  Ylva Haasum; Johan Fastbom; Kristina Johnell
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

5.  Association between osteoarthritis and the incidence of Parkinson's disease in the United Kingdom.

Authors:  Louis Jacob; Lee Smith; Ai Koyanagi; Alexis Schnitzler; Jae Il Shin; Karel Kostev
Journal:  Clin Park Relat Disord       Date:  2021-11-24

6.  Influences of Chronic Mild Stress Exposure on Motor, Non-Motor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP/Probenecid Induced Neurotoxicity in Mice.

Authors:  Udaiyappan Janakiraman; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Musthafa Mohamed Essa; Rajamani Barathidasan; Chidambaram SaravanaBabu; Gilles J Guillemin; Mohammed A S Khan
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

7.  Association between Community Ambulation Walking Patterns and Cognitive Function in Patients with Parkinson's Disease: Further Insights into Motor-Cognitive Links.

Authors:  Aner Weiss; Talia Herman; Nir Giladi; Jeffrey M Hausdorff
Journal:  Parkinsons Dis       Date:  2015-10-29

8.  Parkinson's disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons.

Authors:  Mei Zhu; Giuseppe P Cortese; Clarissa L Waites
Journal:  BMC Biol       Date:  2018-09-10       Impact factor: 7.431

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.